Twist Bioscience Corporation $TWST Shares Sold by Jennison Associates LLC

Jennison Associates LLC lessened its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 2.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 618,933 shares of the company’s stock after selling 15,667 shares during the period. Jennison Associates LLC owned approximately 1.01% of Twist Bioscience worth $19,633,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. D.A. Davidson & CO. grew its holdings in Twist Bioscience by 1.2% during the fourth quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock worth $801,000 after acquiring an additional 305 shares during the period. CWM LLC grew its holdings in Twist Bioscience by 9.4% during the fourth quarter. CWM LLC now owns 4,738 shares of the company’s stock worth $150,000 after acquiring an additional 407 shares during the period. Smartleaf Asset Management LLC grew its holdings in Twist Bioscience by 70.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after acquiring an additional 442 shares during the period. California State Teachers Retirement System grew its holdings in Twist Bioscience by 0.8% in the second quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock valued at $1,994,000 after purchasing an additional 442 shares during the last quarter. Finally, Knights of Columbus Asset Advisors LLC grew its holdings in Twist Bioscience by 2.8% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 23,122 shares of the company’s stock valued at $651,000 after purchasing an additional 628 shares during the last quarter.

Twist Bioscience Trading Up 3.3%

Shares of TWST opened at $60.40 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $66.06. The firm has a 50 day simple moving average of $50.46 and a 200-day simple moving average of $40.99. The stock has a market cap of $3.70 billion, a price-to-earnings ratio of -47.19 and a beta of 2.22.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The company had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The firm’s quarterly revenue was up 16.9% compared to the same quarter last year. Equities analysts forecast that Twist Bioscience Corporation will post -1.86 EPS for the current fiscal year.

Analysts Set New Price Targets

TWST has been the topic of several research reports. Evercore upped their target price on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a report on Friday, March 27th. Barclays upped their price target on shares of Twist Bioscience from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Tuesday, April 14th. Finally, Guggenheim upped their price target on shares of Twist Bioscience from $50.00 to $55.00 and gave the company a “buy” rating in a report on Monday, March 30th. Seven research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.13.

Insider Buying and Selling at Twist Bioscience

In related news, CEO Emily M. Leproust sold 8,061 shares of the stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $65.29, for a total transaction of $526,302.69. Following the sale, the chief executive officer owned 858,887 shares of the company’s stock, valued at $56,076,732.23. This trade represents a 0.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Chess sold 10,000 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $47.00, for a total value of $470,000.00. Following the sale, the director directly owned 21,084 shares in the company, valued at approximately $990,948. The trade was a 32.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 63,220 shares of company stock valued at $3,265,601. 3.08% of the stock is owned by company insiders.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.